Comparison of Therapeutic Efficacy of Gefitinib As Second-and Third-Line Therapies for Patients with Non-Small Cell Lung Cancer

SONG Zheng-bo,YU Yong-feng,CHEN Zhi-wei,XU Yun-hua,LI Zi-ming,LU Shun

DOI: https://doi.org/10.3781/j.issn.1000-7431.2011.01.011

2011-01-01

Tumor

Abstract:Objective: Gefitinib is generally used in second- or third-line treatment for patients with advanced non-small cell lung cancer (NSCLC). The purpose of this study is to evaluate the prognosis of gefitinib as second-line therapy or third-line therapy in advanced NSCLC. Methods: Medical records and follow-up information of 106 patients with advanced NSCLC were retrospectively reviewed. Sixty-two of 106 were treated with gefitinib as second-line therapy, and 44 were treated with gefitinib as third-line therapy. Survival analysis was evaluated by using Kaplan-Meier method. Results: The two groups were comparable in gender (P=0.51), age (P=0.91), performance status score (P=0.42), clinical stage (P=0.18), smoking history (P=0.95) and pathology (P=0.99). The median overall survivals in the second-line and the third-line therapy groups were 24.0 and 21.0 months, respectively (P=0.524). The median progression-free survival in the second-line therapy group was similar to that of the third-line therapy group (2.9 vs 3.2 months, P=0.757). The response rates in the second-line and the third-line therapy groups were 17.7% and 11.4%, respectively (P=0.665), and the disease control rates in these two groups were 48.4% and 54.5%, respectively (P=0.822). The median overall survival of patients with disease control in the second-line therapy group was similar to that of the third-line therapy group (29.7 vs 22.2 months, P=0.611). The toxicities in these two groups are also similar. Conclusion: There is no obvious difference of response rate or survival benefit between second- and third-line therapies with gefitinib. DOI:10.3781/j.issn.1000-7431.2011.01.011